Guillain-Barré syndrome

Seminars in Neurology

Volumn 28, Issue 2, 2008, Pages 152-167

  Burns, Ted M ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Acquired demyelinating neuropathy; Acute inflammatory demyelinating polyradiculoneuropathy (AIDP); Acute motor axonal neuropathy; Demyelinating neuropathy; Guillain Barr syndrome; Inflammatory neuropathy; Miller Fisher syndrome

Indexed keywords

ANALGESIC AGENT; CARBAMAZEPINE; CORTICOSTEROID; ENOXAPARIN; GABAPENTIN; HEPARIN; IMMUNOGLOBULIN; INFLUENZA VACCINE; METHYLPREDNISOLONE; MEXILETINE; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; TETANUS TOXOID; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; TYPHOID VACCINE;

ADJUVANT THERAPY; AUTONOMIC NEUROPATHY; BLOOD CLOTTING DISORDER; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEEP VEIN THROMBOSIS; DIAGNOSTIC ACCURACY; DISABILITY; ELECTRODIAGNOSIS; EMERGENCY CARE; GUILLAIN BARRE SYNDROME; HEART INFARCTION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; HYPOCALCEMIA; HYPOTENSION; IMMUNIZATION; IMMUNOTHERAPY; KIDNEY FAILURE; MENINGISM; NEUROPATHIC PAIN; PATHOPHYSIOLOGY; PATIENT CARE; PATIENT MONITORING; PLASMAPHERESIS; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY FAILURE; REVIEW; SEPTICEMIA; SYMPTOMATOLOGY; VOMITING;

COMMUNICABLE DISEASES; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC IMAGING; ELECTRODIAGNOSIS; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNOTHERAPY; MONITORING, PHYSIOLOGIC; NEURAL CONDUCTION; PERIPHERAL NERVES; TIME FACTORS;

EID: 41149176212     PISSN: 02718235     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1062261     Document Type: Review

References (182)

1. Levin KH. Variants and mimics of Guillain Barré syndrome. Neurologist 2004;10:61-74
2. Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med 1956;255:57-65
3. Prineas JW. Pathology of the Guillain-Barré syndrome. Ann Neurol 1981;9(suppl):6-19
4. Haymaker WE, Kernohan JW. The Landry-Guillain-Barré syndrome: clinicopathologic report of 50 fatal cases and a critique of the literature. Medicine (Baltimore) 1949;28:59-141
5. Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Ann Neurol 1987;22:753-761
6. Plasmapheresis and acute Guillain-Barré syndrome. The Guillain-Barré Syndrome Study Group. Neurology 1985;35: 1096-1104
7. van der Meché FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med 1992;326:1123-1129
8. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Lancet 1997;349:225-230
9. Chio A, Cocito D, Leone M, et al. Guillain-Barré syndrome: a prospective, population-based incidence and outcome survey. Neurology 2003;60:1146-1150
10. Hughes RA, Rees JH. Clinical and epidemiologic features of Guillain-Barré syndrome. J Infect Dis 1997;176(S2):S92-S98
11. Alter M. The epidemiology of Guillain-Barré syndrome. Ann Neurol 1990;27(Suppl):S7-S12
12. Willison HJ. The immunobiology of Guillain-Barré syndromes. J Peripher Nerv Syst 2005;10:94-112
13. Jacobs BC, Rothbarth PH, van der Meché FG, et al. The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology 1998;51:1110-1115
14. Visser LH, van der Meché FG, Meulstee J, et al. Cytomegalovirus infection and Guillain-Barré syndrome: the clinical, electrophysiologic, and prognostic features. Dutch Guillain-Barré Study Group. Neurology 1996;47: 668-673
15. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990;27(suppl):S21-S24
16. Green DM, Ropper AH. Mild Guillain-Barré syndrome. Arch Neurol 2001;58:1098-1101
17. Winer JB, Hughes RA, Osmond C. A prospective study of acute idiopathic neuropathy. I. clinical features and their prognostic value. J Neurol Neurosurg Psychiatry 1988;51: 605-612
18. Hughes RA, Cornblath DR. Guillain-Barré syndrome. Lancet 2005;366:1653-1666
19. Moulin DE, Hagen N, Feasby TE, Amireh R, Hahn A. Pain in Guillain-Barré syndrome. Neurology 1997;48:328-331
20. Ravn H. The Landry-Guillain-Barré syndrome. A survey and a clinical report of 127 cases. Acta Neurol Scand 1967;43(suppl 30):1-64
21. Ropper AH. The Guillain-Barré syndrome. N Engl J Med 1992;326:1130-1136
22. Asbury AK. Diagnostic considerations in Guillain-Barré syndrome. Ann Neurol 1981;9(Suppl):1-5
23. Hughes RA, Wijdicks EF, Benson E, et al. Supportive care for patients with Guillain-Barré syndrome. Arch Neurol 2005;62:1194-1198
24. Gracey DR, McMichan JC, Divertie MB, Howard FM Jr. Respiratory failure in Guillain-Barré syndrome: a 6-year experience. Mayo Clin Proc 1982;57:742-746
25. Lawn ND, Fletcher DD, Henderson RD, Wolter TD, Wijdicks EF. Anticipating mechanical ventilation in Guillain-Barré syndrome. Arch Neurol 2001;58:893-898
26. Massam M, Jones RS. Ventilatory failure in the Guillain-Barré syndrome. Thorax 1980;35:557-558
27. Newton-John H. Prevention of pulmonary complications in severe Guillain-Barré syndrome by early assisted ventilation. Med J Aust 1985;142:444-445
28. Chevrolet JC, Deleamont P. Repeated vital capacity measurements as predictive parameters for mechanical ventilation need and weaning success in the Guillain-Barré syndrome. Am Rev Respir Dis 1991;144:814-818
29. Ropper AH, Kehne SM. Guillain-Barré syndrome: management of respiratory failure. Neurology 1985;35:1662-1665
30. Flachenecker P, Hartung HP, Reiners K. Power spectrum analysis of heart rate variability in Guillain-Barré syndrome. A longitudinal study. Brain 1997;120(Pt 10):1885-1894
31. Flachenecker P, Wermuth P, Hartung HP, Reiners K. Quantitative assessment of cardiovascular autonomic function in Guillain-Barré syndrome. Ann Neurol 1997;42:171-179
32. Lichtenfeld P. Autonomic dysfunction in the Guillain-Barré syndrome. Am J Med 1971;50:772-780
33. Zochodne DW. Autonomic involvement in Guillain-Barré syndrome: a review. Muscle Nerve 1994;17:1145-1155
34. Truax BT. Autonomic disturbances in the Guillain-Barré syndrome. Semin Neurol 1984;4:462-468
35. Tuck RR, McLeod JG. Autonomic dysfunction in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1981;44: 983-990
36. Burns TM, Lawn ND, Low PA, Camilleri M, Wijdicks EF. Adynamic ileus in severe Guillain-Barré syndrome. Muscle Nerve 2001;24:963-965
37. Albers JW, Kelly JJ Jr. Acquired inflammatory demyelinating polyneuropathies: clinical and electrodiagnostic features. Muscle Nerve 1989;12:435-451
38. Albers JW, Donofrio PD, McGonagle TK. Sequential electrodiagnostic abnormalities in acute inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 1985;8:528-539
39. Ropper AH, Wijdicks EF, Shahani BT. Electrodiagnostic abnormalities in 113 consecutive patients with Guillain-Barré syndrome. Arch Neurol 1990;47:881-887
40. Gordon PH, Wilbourn AJ. Early electrodiagnostic findings in Guillain-Barré syndrome. Arch Neurol 2001;58:913-917
41. Cleland JC, Malik K, Thaisetthawatkul P, Herrmann DN, Logigian EL. Acute inflammatory demyelinating polyneuropathy: contribution of a dispersed distal compound muscle action potential to electrodiagnosis. Muscle Nerve 2006; 33:771-777
42. Cornblath DR, Mellits ED, Griffin JW, et al. Motor conduction studies in Guillain-Barré syndrome: description and prognostic value. Ann Neurol 1988;23:354-359
43. McKhann GM, Griffin JW, Cornblath DR, Mellits ED, Fisher RS, Quaskey SA. Plasmapheresis and Guillain-Barré syndrome: analysis of prognostic factors and the effect of plasmapheresis. Ann Neurol 1988;23:347-353
44. Crino PB, Zimmerman R, Laskowitz D, Raps EC, Rostami AM. Magnetic resonance imaging of the cauda equina in Guillain-Barré syndrome. Neurology 1994;44:1334-1336
45. Gorson KC, Ropper AH, Muriello MA, Blair R. Prospective evaluation of MRI lumbosacral nerve root enhancement in acute Guillain-Barré syndrome. Neurology 1996;47:813-817
46. Weiss MD. Root enhancement in GBS. Neurology 1997; 48:1477
47. Hughes R, Sanders E, Hall S, Atkinson P, Colchester A, Payan P. Subacute idiopathic demyelinating polyradiculoneuropathy. Arch Neurol 1992;49:612-616
48. Oh SJ, Kurokawa K, de Almeida DF, Ryan HF Jr, Claussen GC. Subacute inflammatory demyelinating polyneuropathy. Neurology 2003;61:1507-1512
49. Asbury AK, Arnason BG, Adams RD. The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis. Medicine (Baltimore) 1969;48:173-215
50. Berciano J, Coria F, Monton F, Calleja J, Figols J, LaFarga M. Axonal form of Guillain-Barré syndrome: evidence for macrophage-associated demyelination. Muscle Nerve 1993; 16:744-751
51. Feasby TE, Gilbert JJ, Brown WF, et al. An acute axonal form of Guillain-Barré polyneuropathy. Brain 1986;109 (Pt 6):1115-1126
52. Feasby TE, Gilbert JJ, Brown WF, et al. Acute "axonal" Guillain-Barré polyneuropathy. Neurology 1987;37:357
53. Feasby TE, Hahn AF, Brown WF, Bolton CF, Gilbert JJ, Koopman WJ. Severe axonal degeneration in acute Guillain-Barré syndrome: evidence of two different mechanisms? J Neurol Sci 1993;116:185-192
54. Ropper AH. Severe acute Guillain-Barré syndrome. Neurology 1986;36:429-432
55. Griffin JW, Li CY, Ho TW, et al. Pathology of the motor-sensory axonal Guillain-Barré syndrome. Ann Neurol 1996; 39:17-28
56. Griffin JW, Li CY, Macko C, et al. Early nodal changes in the acute motor axonal neuropathy pattern of the Guillain-Barré syndrome. J Neurocytol 1996;25:33-51
57. Sobue G, Li M, Terao S, et al. Axonal pathology in Japanese Guillain-Barré syndrome: a study of 15 autopsied cases. Neurology 1997;48:1694-1700
58. Hafer-Macko C, Hsieh ST, Li CY, et al. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann Neurol 1996;40:635-644
59. McKhann GM, Cornblath DR, Griffin JW, et al. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol 1993;33:333-342
60. Hiraga A, Mori M, Ogawara K, Hattori T, Kuwabara S. Differences in patterns of progression in demyelinating and axonal Guillain-Barré syndromes. Neurology 2003;61:471-474
61. Hiraga A, Mori M, Ogawara K, et al. Recovery patterns and long term prognosis for axonal Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 2005;76:719-722
62. Overell JR, Willison HJ. Recent developments in Miller Fisher syndrome and related disorders. Curr Opin Neurol 2005;18:562-566
63. Yuki N, Taki T, Takahashi M, et al. Molecular mimicry between GQ1b ganglioside and lipopolysaccharides of Campylobacter jejuni isolated from patients with Fisher's syndrome. Ann Neurol 1994;36:791-793
64. Ogawara K, Kuwabara S, Yuki N. Fisher syndrome or Bickerstaff brainstem encephalitis? Anti-GQ1b IgG antibody syndrome involving both the peripheral and central nervous systems. Muscle Nerve 2002;26:845-849
65. Chaudhry F, Gee KE, Vaphiades MS, Biller J, Jay W. GQ1b antibody testing in Guillain-Barré syndrome and variants. Semin Ophthalmol 2006;21:223-227
66. Radziwill AJ, Steck AJ, Borruat FX, Bogousslavsky J. Isolated internal ophthalmoplegia associated with IgG anti-GQ1b antibody. Neurology 1998;50:307
67. Odaka M, Yuki N, Yamada M, et al. Bickerstaff's brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain-Barré syndrome. Brain 2003;126: 2279-2290
68. Chiba A, Kusunoki S, Shimizu T, Kanazawa I. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol 1992;31:677-679
69. Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies. Neurology 1993;43:1911-1917
70. Onodera M, Mori M, Koga M, et al. Acute isolated bulbar palsy with anti-GT1a IgG antibody subsequent to Campylobacter jejuni enteritis. J Neurol Sci 2002;205:83-84
71. Kashihara K, Shiro Y, Koga M, Yuki N. IgG anti-GT1a antibodies which do not cross react with GQ1b ganglioside in a pharyngeal-cervical-brachial variant of Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1998;65:799
72. Nagashima T, Koga M, Odaka M, Hirata K, Yuki N. Clinical correlates of serum anti-GT1a IgG antibodies. J Neurol Sci 2004;219:139-145
73. Nishimoto Y, Odaka M, Hirata K, Yuki N. Usefulness of anti-GQ1b IgG antibody testing in Fisher syndrome compared with cerebrospinal fluid examination. J Neuroimmunol 2004;148:200-205
74. Fross RD, Daube JR. Neuropathy in the Miller Fisher syndrome: clinical and electrophysiologic findings. Neurology 1987;37:1493-1498
75. Nagaoka U, Kato T, Kurita K, et al. Cranial nerve enhancement on three-dimensional MRI in Miller Fisher Syndrome. Neurology 1996;47:1601-1602
76. Mori M, Kuwabara S, Fukutake T, Yuki N, Hattori T. Clinical features and prognosis of Miller Fisher syndrome. Neurology 2001;56:1104-1106
77. Willison HJ. Ganglioside complexes as targets for antibodies in Miller Fisher syndrome. J Neurol Neurosurg Psychiatry 2006;77:1002-1003
78. Schaublin GA, Michet CJ Jr, Dyck PJ, Burns TM. An update on the classification and treatment of vasculitic neuropathy. Lancet Neurol 2005;4:853-865
79. Mori K, Hattori N, Sugiura M, et al. Chronic inflammatory demyelinating polyneuropathy presenting with features of GBS. Neurology 2002;58:979-982
80. Keesey JC. Clinical evaluation and management of myasthenia gravis. Muscle Nerve 2004;29:484-505
81. Cherington M. Clinical spectrum of botulism. Muscle Nerve 1998;21:701-710
82. Li J, Loeb JA, Shy ME, et al. Asymmetric flaccid paralysis: a neuromuscular presentation of West Nile virus infection. Ann Neurol 2003;53:703-710
83. Jeha LE, Sila CA, Lederman RJ, Prayson RA, Isada CM, Gordon SM. West Nile virus infection: a new acute paralytic illness. Neurology 2003;61:55-59
84. Halperin JJ. Lyme disease and the peripheral nervous system. Muscle Nerve 2003;28:133-143
85. Steere AC. Lyme disease. N Engl J Med 2001;345:115-125
86. Donofrio PD, Wilbourn AJ, Albers JW, Rogers L, Salanga V, Greenberg HS. Acute arsenic intoxication presenting as Guillain-Barré-like syndrome. Muscle Nerve 1987;10:114-120
87. Grattan-Smith PJ, Morris JG, Johnston HM, et al. Clinical and neurophysiological features of tick paralysis. Brain 1997;120(Pt 11):1975-1987
88. Vedanarayanan VV, Evans OB, Subramony SH. Tick paralysis in children: electrophysiology and possibility of misdiagnosis. Neurology 2002;59:1088-1090
89. Albers JW, Fink JK. Porphyric neuropathy. Muscle Nerve 2004;30:410-422
90. Calderon-Gonzalez R, Rizzi-Hernandez H. Buckthorn polyneuropathy. N Engl J Med 1967;277:69-71
91. Piradov MA, Pirogov VN, Popova LM, Avdunina IA. Diphtheritic polyneuropathy: clinical analysis of severe forms. Arch Neurol 2001;58:1438-1442
92. Snider WD, Simpson DM, Nielsen S, Gold JW, Metroka CE, Posner JB. Neurological complications of acquired immune deficiency syndrome: analysis of 50 patients. Ann Neurol 1983;14:403-418
93. Roullet E, Assuerus V, Gozlan J, et al. Cytomegalovirus multifocal neuropathy in AIDS: analysis of 15 consecutive cases. Neurology 1994;44:2174-2182
94. Hafer-Macko CE, Sheikh KA, Li CY, et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol 1996;39:625-635
95. Ilyas AA, Willison HJ, Quarles RH, et al. Serum antibodies to gangliosides in Guillain-Barré syndrome. Ann Neurol 1988;23:440-447
96. Oomes PG, Jacobs BC, Hazenberg MP, Bänffer JR, van der Meché FG. Anti-GM1 IgG antibodies and Campylobacter bacteria in Guillain-Barré syndrome: evidence of molecular mimicry. Ann Neurol 1995;38:170-175
97. Sheikh KA, Nachamkin I, Ho TW, et al. Campylobacter jejuni lipopolysaccharides in Guillain-Barré syndrome: molecular mimicry and host susceptibility. Neurology 1998; 51:371-378
98. Vriesendorp FJ, Mishu B, Blaser MJ, Koski CL. Serum antibodies to GM1, GD1b, peripheral nerve myelin, and Campylobacter jejuni in patients with Guillain-Barré syndrome and controls: correlation and prognosis. Ann Neurol 1993;34:130-135
99. Willison HJ. Ganglioside complexes: new autoantibody targets in Guillain-Barré syndromes. Nat Clin Pract Neurol 2005;1:2-3
100. Olsson Y. Topographical differences in the vascular permeability of the peripheral nervous system. Acta Neuropathol 1968;10:26-33
101. Ho TW, Mishu B, Li CY, et al. Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 1995;118 (Pt 3):597-605
102. Yuki N, Taki T, Inagaki F, et al. A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure. J Exp Med 1993;178: 1771-1775
103. Ho TW, Li CY, Cornblath DR, et al. Patterns of recovery in the Guillain-Barré syndromes. Neurology 1997;48:695-700
104. Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miller Fisher syndrome. Brain Res 1997;745:32-36
105. Bril V, Use WK, Pearce R, Dhanani A, Sutton D, Kong K. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome. Neurology 1996;46: 100-103
106. Donofrio PD. Immunotherapy of idiopathic inflammatory neuropathies. Muscle Nerve 2003;28:273-292
107. Hughes RA, Wijdicks EF, Barohn R, et al. Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2003;61: 736-740
108. Plasma exchange in Guillain-Barré syndrome: one-year follow-up. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Ann Neurol 1992;32:94-97
109. McKhann GM, Griffin JW, Cornblath DR, Mellits ED, Fisher RS, Quaskey SA. Plasmapheresis and Guillain-Barré syndrome: analysis of prognostic factors and the effect of plasmapheresis. Ann Neurol 1988;23:347-353
110. McKhann GM, Griffin JW, Cornblath DR, Quaskey SA, Mellits ED. Role of therapeutic plasmapheresis in the acute Guillain-Barré syndrome. J Neuroimmunol 1988;20:297-300
111. The French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Appropriate number of plasma exchanges in Guillain-Barré syndrome. Ann Neurol 1997; 41:298-306
112. Abd-Allah SA, Jansen PW, Ashwal S, Perkin RM. Intravenous immunoglobulin as therapy for pediatric Guillain-Barré syndrome. J Child Neurol 1997;12:376-380
113. Jansen PW, Perkin RM, Ashwal S. Guillain-Barré syndrome in childhood: natural course and efficacy of plasmapheresis. Pediatr Neurol 1993;9:16-20
114. Jones HR. Childhood Guillain-Barré syndrome: clinical presentation, diagnosis, and therapy. J Child Neurol 1996; 11:4-12
115. Vallée L, Dulac O, Nuyts JP, Leclerc F, Vamecq J. Intravenous immune globulin is also an efficient therapy of acute Guillain-Barré syndrome in affected children. Neuropediatrics 1993;24:235-236
116. Epstein MA, Sladky JT. The role of plasmapheresis in childhood Guillain-Barré syndrome. Ann Neurol 1990;28: 65-69
117. Raphaël JC, Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev 2001;(2):CD001798
118. Esperou H, Jars-Guincestre MC, Bolgert F, Raphael JC, Durand-Zaleski I. Cost analysis of plasma-exchange therapy for the treatment of Guillain-Barré syndrome. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Intensive Care Med 2000;26: 1094-1100
119. Osterman PO, Fagius J, Lundemo G, et al. Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 1984;2:1296-1299
120. Yuki N, Tagawa Y, Hirata K. Minimal number of plasma exchanges needed to reduce immunoglobulin in Guillain-Barré syndrome. Neurology 1998;51:875-877
121. Lehmann HC, Hartung HP, Hetzel GR, Stuve O, Kieseier BC. Plasma exchange in neuroimmunological disorders: part 2. Treatment of neuromuscular disorders. Arch Neurol 2006;63:1066-1071
122. Dalakas MC. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther 2004;102:177-193
123. Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 2004;291:2367-2375
124. Thornton CA, Ballow M. Safety of intravenous immunoglobulin. Arch Neurol 1993;50:135-136
125. Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial prednisolone in acute polyneuropathy. Lancet 1978;2:750-753
126. Hughes RA, van Der Meché FG. Corticosteroids for treating Guillain-Barré syndrome. Cochrane Database Syst Rev 2000;(3):CD001446
127. Hughes RA, Swan AV, van Koningsveld R, van Doorn PA. Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev 2006;(2):CD001446
128. van Koningsveld R, Schmitz PI, Meché FG, et al. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial. Lancet 2004;363:192-196
129. Okamiya S, Ogino M, Ogino Y, et al. Tryptophan-immobilized column-based immunoadsorption as the choice method for plasmapheresis in Guillain- Barré syndrome. Ther Apher Dial 2004;8:248-253
130. Haupt WF, Rosenow F, van der Ven C, Birkmann C. Immunoadsorption in Guillain-Barré syndrome and myasthenia gravis. Ther Apher 2000;4:195-197
131. Haupt WF, Rosenow F, van der Ven C, Borberg H, Pawlik G. Sequential treatment of Guillain-Barré syndrome with extracorporeal elimination and intravenous immunoglobulin. J Neurol Sci 1996;137:145-149
132. Romano JG, Rotta FT, Potter P, et al. Relapses in the Guillain-Barré syndrome after treatment with intravenous immune globulin or plasma exchange. Muscle Nerve 1998; 21:1327-1330
133. Visser LH, van der Meché FG, Meulstee J, van Doorn PA. Risk factors for treatment related clinical fluctuations in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. J Neurol Neurosurg Psychiatry 1998;64:242-244
134. Mori M, Kuwabara S, Fukutake T, Hattori T. Intravenous immunoglobulin therapy for Miller Fisher syndrome. Neurology 2007;68:1144-1146
135. Mori M, Kuwabara S, Fukutake T, Hattori T. Plasmapheresis and Miller Fisher syndrome: analysis of 50 consecutive cases. J Neurol Neurosurg Psychiatry 2002;72:680
136. Overell JR, Hsieh S, Odaka M, Yuki N, Willison HJ. Treatment for Fisher syndrome, Bickerstaffs brainstem encephalitis and related disorders. Cochrane Database Syst Rev 2007;1:CD004761
137. Fletcher DD, Lawn ND, Wolter TD, Wijdicks EF. Long-term outcome in patients with Guillain-Barré syndrome requiring mechanical ventilation. Neurology 2000;54:2311-2315
138. Gold R, Bayas A, Toyka KV. Autoimmune neuropathies-current aspects of immunopathologic diagnostics and therapy. Nervenarzt 2005;76:1009-1021; quiz 1022-1023
139. Sunderrajan EV, Davenport J. The Guillain-Barré syndrome: pulmonary-neurologic correlations. Medicine (Baltimore) 1985;64:333-341
140. Pontoppidan H, Geffin B, Lowenstein E. Acute respiratory failure in the adult. 2. N Engl J Med 1972;287:743-752
141. Lawn ND, Wijdicks EF. Post-intubation pulmonary function test in Guillain-Barré syndrome. Muscle Nerve 2000;23:613-616
142. Durand MC, Porcher R, Orlikowski D, et al. Clinical and electrophysiological predictors of respiratory failure in Guillain-Barré syndrome: a prospective study. Lancet Neurol 2006;5:1021-1028
143. Sharshar T, Chevret S, Bourdain F, Raphael JCFrench Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Early predictors of mechanical ventilation in Guillain-Barré syndrome. Crit Care Med 2003;31: 278-283
144. Durand MC, Lofaso F, Lefaucheur JP, et al. Electrophysiology to predict mechanical ventilation in Guillain-Barré syndrome. Eur J Neurol 2003;10:39-44
145. Henderson RD, Lawn ND, Fletcher DD, McClelland RL, Wijdicks EF. The morbidity of Guillain-Barré syndrome admitted to the intensive care unit. Neurology 2003;60:17-21
146. Holdgaard HO, Pedersen J, Jensen RH, et al. Percutaneous dilatational tracheostomy versus conventional surgical tracheostomy. A clinical randomised study. Acta Anaesthesiol Scand 1998;42:545-550
147. Emmons PR, Blume WT, DuShane JW. Cardiac monitoring and demand pacemaker in Guillain-Barré syndrome. Arch Neurol 1975;32:59-61
148. Favre H, Foex P, Guggisberg M. Use of demand pacemaker in a case of Guillain-Barré syndrome. Lancet 1970;1:1062-1063
149. Singh NK, Jaiswal AK, Misra S, Srivastava PK. Assessment of autonomic dysfunction in Guillain-Barré syndrome and its prognostic implications. Acta Neurol Scand 1987;75: 101-105
150. McLeod JG. Invited review: autonomic dysfunction in peripheral nerve disease. Muscle Nerve 1992;15:3-13
151. Clarke E, Bayliss RIS, Cooper R. Landry-Guillain-Barré syndrome: cardiovascular complications; treatment with A.C.T.H. and cortisone. BMJ 1954;2(4903):1504-1507
152. Kogan BA, Solomon MH, Diokno AC. Urinary retention secondary to Landry-Guillain-Barré syndrome. J Urol 1981; 126:643-644
153. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in medical patients with enoxaparin study group. N Engl J Med 1999;341:793-800
154. Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 1988;318:1162-1173
155. Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. Ann Surg 1988;208:227-240
156. Pandey CK, Bose N, Garg G, et al. Gabapentin for the treatment of pain in Guillain-Barré syndrome: a double-blinded, placebo-controlled, crossover study. Anesth Analg 2002;95:1719-1723
157. Tripathi M, Kaushik S. Carbamezapine for pain management in Guillain-Barré syndrome patients in the intensive care unit. Crit Care Med 2000;28:655-658
158. Meythaler JM. Rehabilitation of Guillain-Barré syndrome. Arch Phys Med Rehabil 1997;78:872-879
159. Herbison GJ, Jaweed MM, Ditunno JF Jr. Exercise therapies in peripheral neuropathies. Arch Phys Med Rehabil 1983;64:201-205
160. Pitetti KH, Barrett PJ, Abbas D. Endurance exercise training in Guillain-Barré syndrome. Arch Phys Med Rehabil 1993;74:761-765
161. Cooke JF, Orb A. The recovery phase in Guillain-Barré syndrome: moving from dependency to independence. Rehabil Nurs 2003;28:105-108, 130
162. Bernsen RA, de Jager AE, Schmitz PI, van der Meché FG. Long-term impact on work and private life after Guillain-Barré syndrome. J Neurol Sci 2002;201:13-17
163. Bernsen RA, de Jager AE, van der Meché FG, Suurmeijer TP. How Guillain-Barré patients experience their functioning after 1 year. Acta Neurol Scand 2005;112:51-56
164. Rees JH, Thompson RD, Smeeton NC, Hughes RA. Epidemiological study of Guillain-Barré syndrome in south east England. J Neurol Neurosurg Psychiatry 1998;64:74-77
165. The prognosis and main prognostic indicators of Guillain-Barré syndrome. A multicentre prospective study of 297 patients. The Italian Guillain-Barré Study Group. Brain 1996;119(Pt 6):2053-2061
166. Bernsen RA, de Jager AE, Schmitz PI, van der Meché FG. Residual physical outcome and daily living 3 to 6 years after Guillain-Barré syndrome. Neurology 1999;53:409-410
167. Prevots DR, Sutter RW. Assessment of Guillain-Barré syndrome mortality and morbidity in the United States: implications for acute flaccid paralysis surveillance. J Infect Dis 1997;175(S1):S151-S155
168. van Koningsveld R, Steyerberg EW, Hughes RA, Swan AV, van Doorn PA, Jacobs BC. A clinical prognostic scoring system for Guillain-Barré syndrome. Lancet Neurol 2007;6: 589-594
169. Bradshaw DY, Jones HR Jr. Guillain-Barré syndrome in children: clinical course, electrodiagnosis, and prognosis. Muscle Nerve 1992;15:500-506
170. Vajsar J, Fehlings D, Stephens D. Long-term outcome in children with Guillain-Barré syndrome. J Pediatr 2003;142: 305-309
171. de Jager AE, Minderhoud JM. Residual signs in severe Guillain- Barré syndrome: analysis of 57 patients. J Neurol Sci 1991;104:151-156
172. Garssen MP, Van Koningsveld R, Van Doorn PA. Residual fatigue is independent of antecedent events and disease severity in Guillain-Barré syndrome. J Neurol 2006;253: 1143-1146
173. Merkies IS, Schmitz PI, Samijn JP, van der Meché FG, van Doorn PA. Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology 1999;53:1648-1654
174. Garssen MP, van Doorn PA, Visser GH. Nerve conduction studies in relation to residual fatigue in Guillain-Barré syndrome. J Neurol 2006;253:851-856
175. Garssen MP, Schmitz PI, Merkies IS, Jacobs BC, van der Meché FG, van Doorn PA. Amantadine for treatment of fatigue in Guillain-Barré syndrome: a randomised, double blind, placebo controlled, crossover trial. J Neurol Neurosurg Psychiatry 2006;77:61-65
176. Garssen MP, Bussmann JB, Schmitz PI, et al. Physical training and fatigue, fitness, and quality of life in Guillain-Barré syndrome and CIDP. Neurology 2004;63:2393-2395
177. Hughes RA, Charlton J, Latinovic R, Gulliford MC. No association between immunization and Guillain-Barré syndrome in the United Kingdom, 1992 to 2000. Arch Intern Med 2006;166:1301-1304
178. Juurlink DN, Stukel TA, Kwong J, et al. Guillain-Barré syndrome after influenza vaccination in adults: a population-based study. Arch Intern Med 2006;166:2217-2221
179. Lasky T, Terracciano GJ, Magder L, et al. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med 1998;339:1797-1802
180. Fenichel GM. Assessment: neurologic risk of immunization: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology 1999;52:1546-1552
181. Wijdicks EF, Fletcher DD, Lawn ND. Influenza vaccine and the risk of relapse of Guillain-Barré syndrome. Neurology 2000;55:452-453
182. Pritchard J, Mukherjee R, Hughes RA. Risk of relapse of Guillain-Barré syndrome or chronic inflammatory demyelinating polyradiculoneuropathy following immunisation. J Neurol Neurosurg Psychiatry 2002;73:348-349